Publication: The involvement of selenium in type 2 diabetes development related to obesity and low grade inflammation
2
Issued Date
2021-01-01
Resource Type
ISSN
11787007
Other identifier(s)
2-s2.0-85105086783
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. Vol.14, (2021), 1669-1680
Suggested Citation
Rossukon Wongdokmai, Prapimporn Chattranukulchai Shantavasinkul, Suwannee Chanprasertyothin, Pachara Panpunuan, Dujrudee Matchariyakul, Piyamitr Sritara, Jintana Sirivarasai The involvement of selenium in type 2 diabetes development related to obesity and low grade inflammation. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. Vol.14, (2021), 1669-1680. doi:10.2147/DMSO.S303146 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/78759
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
The involvement of selenium in type 2 diabetes development related to obesity and low grade inflammation
Abstract
Background: Effects of the micronutrient selenium have been proposed in obesity and type 2 diabetes mellitus (T2DM) that involve impairments in glucose metabolic pathways and the insulin signaling cascade, mediated through oxidative stress and inflammation. However, the evidence collected to date through animal and epidemiologic studies has been inconclusive. Therefore, in the present study, we aimed to evaluate the relationships of selenium status and inflammation with T2DM and obesity. Methods: Participants in the re-survey of the Electricity Generating Authority of Thailand (EGAT)2 study conducted in 2013 (N=655, age 45–60 years) were allocated to three groups based on their body mass index (World Health Organization Asia-Pacific Classification), and their serum selenium and high-sensitivity C-reactive protein (hs-CRP) concentrations and other clinical parameters were compared. Results: Significant differences in serum selenium and hs-CRP among the groups were associated with differences in fasting blood glucose and glycated hemoglobin, as well as differences in the prevalence of prediabetes or T2DM. The adjusted odds ratios (ORs) (95% confidence intervals) for prediabetes or diabetes were 1.991 (1.318–3.009) and 3.786 (2.-087–6.896) for the lowest and highest tertiles of serum selenium concentration in the entire sample and obese participants, respectively. Furthermore, the rising extent of hs-CRP increased the significantly associated with prediabetes or diabetes (adjusted ORs; 2.268 for the entire sample, 4.043 for the overweight and 1.910 for the obesity). Conclusion: Selenium status may be linked to both obesity and T2DM through its effects on signaling pathways. Further nutrigenomic studies are required to clarify the relationship between selenium and metabolic diseases.